Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia
ABSTRACT: In a nonblinded, therapeutic trial conducted in Colombia, 1.25–1.5 grams of mefloquine base given as a single oral dose or as 250 mg a day for 5–6 consecutive days was not efficacious in the treatment of New World cutaneous leishmaniasis. The drug had cured only 30.8% of patients with leis...
- Autores:
-
Muñoz Herrera, Diana Lorena
Puerta Álvarez, Juan Alberto
Vélez Bernal, Iván Darío
Hendrickx, Erik Paul
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 1998
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/32064
- Acceso en línea:
- https://hdl.handle.net/10495/32064
- Palabra clave:
- Antimaláricos
Antimalarials
Leishmaniasis Cutánea
Leishmaniasis, Cutaneous
Mefloquina
Mefloquine
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
UDEA2_9bcfd0db984daf43b2600ff2d1a3d9c2 |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/32064 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| title |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| spellingShingle |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia Antimaláricos Antimalarials Leishmaniasis Cutánea Leishmaniasis, Cutaneous Mefloquina Mefloquine |
| title_short |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| title_full |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| title_fullStr |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| title_full_unstemmed |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| title_sort |
Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in Colombia |
| dc.creator.fl_str_mv |
Muñoz Herrera, Diana Lorena Puerta Álvarez, Juan Alberto Vélez Bernal, Iván Darío Hendrickx, Erik Paul |
| dc.contributor.author.none.fl_str_mv |
Muñoz Herrera, Diana Lorena Puerta Álvarez, Juan Alberto Vélez Bernal, Iván Darío Hendrickx, Erik Paul |
| dc.subject.decs.none.fl_str_mv |
Antimaláricos Antimalarials Leishmaniasis Cutánea Leishmaniasis, Cutaneous Mefloquina Mefloquine |
| topic |
Antimaláricos Antimalarials Leishmaniasis Cutánea Leishmaniasis, Cutaneous Mefloquina Mefloquine |
| description |
ABSTRACT: In a nonblinded, therapeutic trial conducted in Colombia, 1.25–1.5 grams of mefloquine base given as a single oral dose or as 250 mg a day for 5–6 consecutive days was not efficacious in the treatment of New World cutaneous leishmaniasis. The drug had cured only 30.8% of patients with leishmaniasis skin lesions by the 10th week after start of therapy as compared with a 27.9% complete cicatrization rate in historical controls treated with placebo tablets and an 86.3% cicatrization rate in historical controls who received meglumine antimoniate, 20 mg/ kg/day intramuscularly for 20 days, with no upper limit to daily dose. It is concluded that a single course treatment with mefloquine is not indicated as monotherapy in the treatment of Colombian cutaneous leishmaniasis primarily due to L. panamensis. |
| publishDate |
1998 |
| dc.date.issued.none.fl_str_mv |
1998 |
| dc.date.accessioned.none.fl_str_mv |
2022-11-15T22:23:19Z |
| dc.date.available.none.fl_str_mv |
2022-11-15T22:23:19Z |
| dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.local.spa.fl_str_mv |
Artículo de investigación |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. 1998 Dec;59(6):889-92. doi: 10.4269/ajtmh.1998.59.889. |
| dc.identifier.issn.none.fl_str_mv |
0002-9637 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/32064 |
| dc.identifier.doi.none.fl_str_mv |
10.4269/ajtmh.1998.59.889 |
| dc.identifier.eissn.none.fl_str_mv |
1476-1645 |
| identifier_str_mv |
Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. 1998 Dec;59(6):889-92. doi: 10.4269/ajtmh.1998.59.889. 0002-9637 10.4269/ajtmh.1998.59.889 1476-1645 |
| url |
https://hdl.handle.net/10495/32064 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Am. J. Trop. Med. Hyg. |
| dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.format.extent.spa.fl_str_mv |
4 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
American Society of Tropical Medicine and Hygiene |
| dc.publisher.group.spa.fl_str_mv |
Programa de Estudio y Control de Enfermedades Tropicales (PECET) |
| dc.publisher.place.spa.fl_str_mv |
Baltimore, Estados Unidos |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstream/10495/32064/2/license_rdf https://bibliotecadigital.udea.edu.co/bitstream/10495/32064/3/license.txt https://bibliotecadigital.udea.edu.co/bitstream/10495/32064/4/Mu%c3%b1oz_Diana_1998_MefloquineTreatmentLeishmaniasis.pdf |
| bitstream.checksum.fl_str_mv |
1646d1f6b96dbbbc38035efc9239ac9c 8a4605be74aa9ea9d79846c1fba20a33 78fd9735191ce6524a8ad92a69a285e7 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
| repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
| _version_ |
1812173296041459712 |
| spelling |
Muñoz Herrera, Diana LorenaPuerta Álvarez, Juan AlbertoVélez Bernal, Iván DaríoHendrickx, Erik Paul2022-11-15T22:23:19Z2022-11-15T22:23:19Z1998Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg. 1998 Dec;59(6):889-92. doi: 10.4269/ajtmh.1998.59.889.0002-9637https://hdl.handle.net/10495/3206410.4269/ajtmh.1998.59.8891476-1645ABSTRACT: In a nonblinded, therapeutic trial conducted in Colombia, 1.25–1.5 grams of mefloquine base given as a single oral dose or as 250 mg a day for 5–6 consecutive days was not efficacious in the treatment of New World cutaneous leishmaniasis. The drug had cured only 30.8% of patients with leishmaniasis skin lesions by the 10th week after start of therapy as compared with a 27.9% complete cicatrization rate in historical controls treated with placebo tablets and an 86.3% cicatrization rate in historical controls who received meglumine antimoniate, 20 mg/ kg/day intramuscularly for 20 days, with no upper limit to daily dose. It is concluded that a single course treatment with mefloquine is not indicated as monotherapy in the treatment of Colombian cutaneous leishmaniasis primarily due to L. panamensis.COL00150994application/pdfengAmerican Society of Tropical Medicine and HygienePrograma de Estudio y Control de Enfermedades Tropicales (PECET)Baltimore, Estados Unidosinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTArtículo de investigaciónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-nd/4.0/Lack of efficacy of mefloquine in the treatment of new world cutaneous leishmaniasis in ColombiaAntimaláricosAntimalarialsLeishmaniasis CutáneaLeishmaniasis, CutaneousMefloquinaMefloquineAm. J. Trop. Med. Hyg.American Journal of Tropical Medicine and Hygiene889892596CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstream/10495/32064/2/license_rdf1646d1f6b96dbbbc38035efc9239ac9cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/32064/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALMuñoz_Diana_1998_MefloquineTreatmentLeishmaniasis.pdfMuñoz_Diana_1998_MefloquineTreatmentLeishmaniasis.pdfArtículo de investigaciónapplication/pdf63771https://bibliotecadigital.udea.edu.co/bitstream/10495/32064/4/Mu%c3%b1oz_Diana_1998_MefloquineTreatmentLeishmaniasis.pdf78fd9735191ce6524a8ad92a69a285e7MD5410495/32064oai:bibliotecadigital.udea.edu.co:10495/320642022-11-15 17:26:06.671Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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 |